Recorded fact · drug.trial_access

drug.trial_access for rivaroxaban

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 44bd7243 resolves to.

The record

Fact id	`44bd7243485b0f388eae73e6`
Entity	drug: rivaroxaban
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "RIVAROXABAN",
 "recruitingInterventionalCount": 67,
 "notYetRecruitingCount": 21,
 "byPhase": {
  "PHASE3": 13,
  "NA": 16,
  "PHASE4": 30,
  "PHASE2": 1,
  "EARLY_PHASE1": 3,
  "PHASE1": 2,
  "PHASE2/PHASE3": 2
 },
 "trials": [
  {
   "nctId": "NCT07318610",
   "briefTitle": "Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Regeneron Pharmaceuticals",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2026-07-10",
   "conditions": [
    "Peripheral Artery Disease (PAD)"
   ],
   "countries": [
    "United States",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07318610"
  },
  {
   "nctId": "NCT05701917",
   "briefTitle": "DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Inari Medical",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2023-01-06",
   "conditions": [
    "Venous Thromboembolism",
    "Deep Venous Thrombosis",
    "Post-Thrombotic Syndrome"
   ],
   "countries": [
    "United States",
    "Austria",
    "Finland",
    "Germany",
    "Switzerland",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05701917"
  },
  {
   "nctId": "NCT07907211",
   "briefTitle": "Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Chen Lijuan",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2024-02-01",
   "conditions": [
    "Multiple Myeloma",
    "Venous Thromboembolism (VTE)"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07907211"
  },
  {
   "nctId": "NCT06978439",
   "briefTitle": "Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Children's Hospital of Fudan University",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-22",
   "startDate": "2024-01-10",
   "conditions": [
    "Kawasaki Disease",
    "Pilot Study",
    "Coronary Artery Aneurysm"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06978439"
  },
  {
   "nctId": "NCT06401616",
   "briefTitle": "Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Odense University Hospital",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-21",
   "startDate": "2024-05-21",
   "conditions": [
    "Atrial Fibrillation",
    "Left Atrial Appendage Absent",
    "Anticoagulant Adverse Reaction"
   ],
   "countries": [
    "Denmark"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06401616"
  },
  {
   "nctId": "NCT07869615",
   "briefTitle": "Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Military Hospital of Tunis",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-16",
   "startDate": "2026-09-15",
   "conditions": [
    "Total Knee Arthroplasty",
    "Venous Thromboembolism"
   ],
   "countries": [
    "Tunisia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07869615"
  },
  {
   "nctId": "NCT05775965",
   "briefTitle": "HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot)",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "University of Calgary",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-09",
   "startDate": "2024-05-21",
   "conditions": [
    "Hip Fractures"
   ],
   "countries": [
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05775965"
  },
  {
   "nctId": "NCT04642430",
   "briefTitle": "COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Ottawa Hospital Research Institute",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-01",
   "startDate": "2021-07-06",
   "conditions": [
    "Atrial Fibrillation"
   ],
   "countries": [
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04642430"
  },
  {
   "nctId": "NCT06571149",
   "briefTitle": "Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Insel Gruppe AG, University Hospital Bern",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-09-30",
   "startDate": "2025-03-14",
   "conditions": [
    "Ischemic Stroke"
   ],
   "countries": [
    "Austria",
    "Belgium",
    "Canada",
    "Finland",
    "France",
    "Germany",
    "Greece",
    "Netherlands",
    "Norway",
    "Portugal"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06571149"
  },
  {
   "nctId": "NCT06650501",
   "briefTitle": "Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "McGill University Health Centre/Research Institute of the McGill University Health Centre",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-09-24",
   "startDate": "2026-01-15",
   "conditions": [
    "Staphylococcus Aureus Endocarditis",
    "Staphylococcus Aureus Septicemia",
    "Staphylococcus Aureus Bacteremia"
   ],
   "countries": [
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06650501"
  },
  {
   "nctId": "NCT06953726",
   "briefTitle": "Comparing the Safety and Efficacy of Apixaban and Rivaroxaban",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "VA Office of Research and Development",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-09-23",
   "startDate": "2026-06-01",
   "conditions": [
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: 446b82ffd4f8aff98024f493885582062d1ce7ca817da515a841acd43c327877.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.